Charles J. Ditkoff Net Worth

The estimated Net Worth of Charles J. Ditkoff is at least $233 mil dollars as of 31 May 2019. Charles Ditkoff owns over 4,099 units of R1 RCM stock worth over $57,878 and over the last 7 years Charles sold RCM stock worth over $174,778.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Charles Ditkoff RCM stock SEC Form 4 insiders trading

Charles has made over 3 trades of the R1 RCM stock since 2018, according to the Form 4 filled with the SEC. Most recently Charles exercised 4,099 units of RCM stock worth $57,878 on 31 May 2019.

The largest trade Charles's ever made was selling 20,635 units of R1 RCM stock on 16 November 2018 worth over $174,778. On average, Charles trades about 7,562 units every 43 days since 2017. As of 31 May 2019 Charles still owns at least 4,099 units of R1 RCM stock.

You can see the complete history of Charles Ditkoff stock trades at the bottom of the page.

What's Charles Ditkoff's mailing address?

Charles's mailing address filed with the SEC is C/O R1 RCM INC., 401 N MICHIGAN AVE, SUITE 2700, CHICAGO, IL, 60611.

Insiders trading at R1 RCM

Over the last 8 years, insiders at R1 RCM have traded over $770,079,900 worth of R1 RCM stock and bought 103,238 units worth $1,376,421 . The most active insiders traders include Achi Series Lllptcp Asc Gp,..., Joseph Gerard Flanagan y John B Iii Henneman. On average, R1 RCM executives and independent directors trade stock every 27 days with the average trade being worth of $7,812,780. The most recent stock trade was executed by John M. Sparby on 6 March 2024, trading 10,046 units of RCM stock currently worth $143,959.

What does R1 RCM do?

R1 RCM Inc. is an American revenue cycle management company servicing hospitals, health systems and physician groups across the United States.

Complete history of Charles Ditkoff stock trades at R1 RCM

R1 RCM executives and stock owners

R1 RCM executives and other stock owners filed with the SEC include:

• Joseph Flanagan,
  President, Chief Executive Officer, Director
• Gary Long,
  Executive Vice President, Chief Commercial Officer
• Joseph Gerard Flanagan,
  Pres, CEO & Director
• Gary S. Long,
  Exec. VP & Chief Commercial Officer
• Richard Evans,
  Senior Vice President, Chief Accounting Officer, Corporate Controller
• Richard B. Evans Jr.,
  Sr. VP, Corp. Controller & Chief Accounting Officer
• Rachel Wilson,
  Exec. VP, CFO & Treasurer
• Alex Mandl,
  Lead Independent Director
• Michael Feiner,
  Independent Director
• Jill Smith,
  Independent Director
• John Henneman,
  Independent Director
• Anthony Tersigni,
  Director
• Anthony Speranzo,
  Independent Director
• Rachel Wilson,
  Chief Financial Officer, Treasurer
• Atif Rahim,
  Senior Vice President - Investor Relations & Business Development
• Vijay Kotte,
  Executive Vice President - Physician Services
• Ian Sacks,
  Independent Director
• Neal Moszkowski,
  Independent Director
• Albert Zimmerli,
  Director
• Vijay Kumar Kotte,
  Exec. VP of Strategy & Corp. Devel. and Chief Solutions Officer
• Sean Radcliffe,
  Exec. VP, Gen. Counsel & Corp. Sec.
• Corey Perman,
  Exec. VP of Compliance & Risk
• Jay Sreedharan,
  Chief Technology & Digital Officer
• John M. Sparby,
  Exec. VP of Operations & Delivery and COO
• Charles J. Ditkoff,
  Director
• Steven J Shulman,
  Director
• Christopher Simon Ricaurte,
  Chief Financial Officer
• Mountain Capital, L.L.C.Coy...,
  
• Pamela L. Spikner,
  Principal Accounting Officer
• Thomas A Lesica,
  Chief Operating Officer
• Bradford Kyle Armbrester,
  Director
• Jeremy Delinsky,
  Director
• David M Dill,
  Director
• Scanlan Agnes Bundy,
  Director
• Lee Rivas,
  Chief Executive Officer
• John M. Sparby,
  President
• Jennifer D. Williams,
  Chief Financial Officer
• Kyle Hicok,
  Chief Commercial Officer